WASHINGTON, Jan 20 (Reuters) - Early evidence shows labeling proposed to sell GlaxoSmithKline’s (GSK.N: Quote, Profile, Research) (GSK.L: Quote, Profile, Research) weight-loss drug Xenical over-the-counter may not lead to safe use, U.S. regulatory staff said in documents released on Friday.
